ABLI — Abliva AB Share News
0.000.00%
Last trade - 00:00- SEK467.94m
- SEK435.27m
Brief: Abliva Q4 Pre-Tax Loss Narrows To SEK 17.6 Mln
Brief: Abliva Nomination Committee To Propose Edwin Moses As Chair of BoD
Brief: Abliva Gets New U.S. Patent For Therapeutic Compound NV354
Brief: Abliva Q3 Pre Tax Loss Narrows To SEK 25.1 Mln
Brief: Abliva Q2 Loss Before Tax Narrows To SEK 20.5 Million
Brief: Abliva Announces Rights Issue Results
Brief: Hadean Ventures Increases Ownership To 28.5%
Brief: Abliva Q4 Net Revenues Lower To SEK 48,000
Brief: Abliva Resolves To Issue Convertibles Worth SEK 26 MlN
Brief: Abliva Q3 Loss Before Tax Narrows To SEK 34.9 Mln
Brief: Abliva Drug Candidate NV354 To Progress To Clinical Development Following Positive Regulatory Review
Brief: Abliva Q2 Loss Before Tax At SEK 30.3 Mln
Brief: Abliva Q1 Loss Before Tax Widens To SEK 21.5 Mln
Brief: Abliva Reports Positive Clinical Results For PMD Drug
Brief: Abliva Receives Gross SEK 80 Mln In Directed Share Issue
Brief: Abliva Reports Completion Of Kl1333 Phase 1A/B Study
Brief: Abliva Q4 Loss Before Tax Narrows To KSEK 13,067
Brief: Abliva Appoints Ellen Donnelly New CEO
Brief: Abliva Appoints Ellen Donnelly As New CEO